Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial

AIMS: This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF). METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippatos, Gerasimos, Pitt, Bertram, Agarwal, Rajiv, Farmakis, Dimitrios, Ruilope, Luis M., Rossing, Peter, Bauersachs, Johann, Mentz, Robert J., Kolkhof, Peter, Scott, Charlie, Joseph, Amer, Bakris, George L., Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Prevention of Hf
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541504/
https://www.ncbi.nlm.nih.gov/pubmed/35239204
http://dx.doi.org/10.1002/ejhf.2469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541504/
https://www.ncbi.nlm.nih.gov/pubmed/35239204
http://dx.doi.org/10.1002/ejhf.2469

Ejemplares similares